Invion Limited (IVX.AX)

0.0030 +0.0010 (+50.00%) At close: 04:10PM AEST

Invion Limited

100 Albert Road
Level 4
Melbourne, VIC 3205
Australia
61 3 9692 7222
https://www.inviongroup.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Thian Chew	Executive Chairman & CEO	422.77k	N/A	N/A
Ms. Melanie Jaye Leydin B.Bus, C.A.	CFO & Non-Executive Director	N/A	N/A	1973
Dr. Dean Naylor	Head of Intellectual Property Development	N/A	N/A	N/A
Mr. Tai Minh Phan	Company Secretary	N/A	N/A	N/A

Amounts are as of 31 December 2024, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Corporate governance

Invion Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.